drugset / Trial / NCT00111631
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Timeline
- Start
- 2005-05
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Metformin | Small molecule | — | — |